Drilldown: Medicines

Other values:

Search

None (78) · (none, never marketed) (1) · Dalmane (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Doral (1) · Doriden (1) · Halcion (1) · Hetlioz (1) · Imovane (1) · Lunesta (1) · Mogadon (1) · Nembutal (1) · Placidyl (1) · ProSom (1) · Quaalude (1) · Restoril (1) · Retin-A, Renova, Atralin, Avita, Tretin-X, Refissa, Altreno; Vesanoid (oral, APL) (1) · Rohypnol (1) · Rozerem (1) · Seconal (1) · Sonata (1) · THIP (1) · Versed (1) · Xyrem (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

5-HT2A agonist (26) · GABAA positive allosteric modulator (15) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · None (3) · GABAA positive allosteric modulator (non-benzodiazepine) (3) · Contains LSA (2) · Contains mescaline (2) · GABAA potentiator and direct activator (2) · Melatonin receptor agonist (2)

Other values:

Search

None (99) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · '"`UNIQ--vote-00000BA0-QINU`"', '"`UNIQ--vote-00000BA1-QINU`"', '"`UNIQ--vote-00000BA2-QINU`"' (1)

None (99) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) · Topical: pea-sized amount to dry face at bedtime, building from 2-3×/week to nightly as tolerated; oral APL: 45 mg/m²/d in divided doses (1)

None (99) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1) · Topical 0.01-0.1% creams, gels, micropsheres, lotions; oral 10 mg capsules (Vesanoid) (1)

None (99) · N/A (never approved) (1) · Topical: nightly; oral APL: 45 mg/m²/d (1)

None (98) · intranasal; rectal and IV reported. (1) · Oral (2) · oral (APL only) (1) · sublingual (1) · Topical (1)

None (98) · 30–60 minutes (1) · Topical: irritation within days; acne improvement 6-12 weeks; oral APL response within days (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (98) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · 8–12 hours (1) · N/A (1)

None (98) · 3–5 hours (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · ~0.5-2 hours (oral)'"`UNIQ--ref-00000BA3-QINU`"' (1)

None (98) · 70–90% (oral) (1) · Not formally characterized in humans. (1) · Topical: minimal systemic absorption with normal skin; oral: variable, induced metabolism with repeated dosing'"`UNIQ--ref-00000BA4-QINU`"' (1)

None (99) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Not established (1)

None (99) · Schedule I (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (1)